CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
CARMESilk develops a novel technology using silk fibroin to prevent chemotherapy-induced hair loss in cancer patients. By selectively capturing the chemotherapeutic agent doxorubicin in the hair matrix, this patient-friendly solution aims to enhance quality of life during treatment, addressing psychological distress an…
This research project, CARMESilk, aims to develop an innovative solution for preventing chemotherapy-induced alopecia (CIA) to improve cancer patients' quality of life. CIA is one of the most distressing side effects of cancer, affecting up to 65% of cancer patients undergoing treatment, causing social withdrawal, decreased self-esteem, and depression.
Doxorubicin, a chemotherapeutic agent from the group of anthracyclines, is used as cancer drug in breast, ovary, bladder, and thyroid cancers, am…
FRIEDRICH-SCHILLER-UNIVERSITÄT JENA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United States, Medford Ma
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
